KR970042506A - 신규한 2-나프타미드 유도체와 이의 치료제로서의 사용 - Google Patents
신규한 2-나프타미드 유도체와 이의 치료제로서의 사용 Download PDFInfo
- Publication number
- KR970042506A KR970042506A KR1019960063733A KR19960063733A KR970042506A KR 970042506 A KR970042506 A KR 970042506A KR 1019960063733 A KR1019960063733 A KR 1019960063733A KR 19960063733 A KR19960063733 A KR 19960063733A KR 970042506 A KR970042506 A KR 970042506A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- naphtamide
- treatment
- butyl
- piperazinyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract 16
- 229960003638 dopamine Drugs 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 6
- 239000000556 agonist Substances 0.000 claims abstract 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 4
- 206010013663 drug dependence Diseases 0.000 claims abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 125000002560 nitrile group Chemical group 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 208000028017 Psychotic disease Diseases 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 208000012201 sexual and gender identity disease Diseases 0.000 claims abstract 3
- 208000015891 sexual disease Diseases 0.000 claims abstract 3
- 208000011117 substance-related disease Diseases 0.000 claims abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 229910052740 iodine Inorganic materials 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 10
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 238000001784 detoxification Methods 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- -1 4-phenylpiperazinyl Chemical group 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
본 발명은 다음의 일반식(Ⅰ)에 상응하는 염기 또는 염 형태의 2-타프타미드 유도체에 관한 것이다.
(Ⅰ)
상기식에서, Z-Y는 N-CH2, C=CH 또는 CH-CH2기를 나타내며 ; R1은 수소원자, 플루오르 원자, 브롬원자 또는 요오드원자 또는 하이드록실기, 메톡시기, 니트릴기 또는 니트로기를 나타내며 : R2는 수소원자 또는 브롬원자 또는 하이드록실기, 메톡시기, 니트릴기 또는 니트로기를 나타내며 ; 상기 R1및 R2치환제는 나프타미드 유니트의 동일한 고리에 함께 위치하거나 또는 각각 하나의 고리에 위치하며 ; R3및 R4는 동일하거나 또는 상이할 수 있고 각각 독립적으로 수소원자 또는 염소원자 또는 메톡시기 또는 메틸기 또는 전자 끄는 기를 나타낸다. 또한 본 발명은 도파민 D3수용체의 국부작용물질로서의 치료용도에 관한 것이다. 본 발명은 도파민 D3수용체를 수반하는 신경정신성 질환, 특히 정신병과 우울증의 치료, 약물의존증의 치료 또는 성적인 장애의 치료에 적용된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 다음의 일반식(Ⅰ)에 상응하는 염기 또는 염 형태의 2-라프타미드 유도체;(Ⅰ)상기식에서, Z-Y는 N-CH2, C=CH 또는 CH-CH2기를 나타내며 ; R1은 수소원자, 플루오르 원자, 브롬원자 또는 요오드원자 또는 하이드록실기, 메톡시기, 니트릴기 또는 니트로기를 나타내며 : R2는 수소원자 또는 브롬원자 또는 하이드록실기, 메톡시기, 니트릴기 또는 니트로기를 나타내며 ; 상기 R1및 R2치환제는 나프타미드 유니트의 동일한 고리에 함께 위치하거나 또는 각각 하나의 고리에 위치하며 ; R3및 R4는 동일하거나 또는 상이할 수 있고 각각 독립적으로 수소원자 또는 염소원자 또는 메톡시기 또는 메틸기 또는 전자 끄는 기를 나타낸다.
- 제1항에 있어서, Z-Y는 N-CH2기인 것을 특징으로 하는 유도체
- 제1항에 있어서, N-[4-(4-2-메톡시페닐)피페라지닐)부틸]-1-메톡시-4-니트로-2-나프타미드; N-[4[(4-페닐-1,2,3,6-X테트라하이드로피리디닐)부틸]-2-나프타미드 ; N-[4-(4-2-메톡시페닐)피페라지닐)부틸]-2-나프타미드 ; N-[4-(4-2-메톡시페닐)피페라지닐)부틸]-1-메톡시-4-시아노-2-나프타미드 ; N-[4-(4-2-메톡시페닐)피페라지닐)부틸]-2-나프타미드 ;N-[4-(4-2-클로로페닐)피페라지닐)부틸]-3-메톡시-2-나프타미드 ; N-[4-(4-2-클로로페닐)피페라지닐)부틸]-2-나프타미드 ; N-[4-(4-3-클로로페닐)피페라지닐)부틸]-2-나프타미드 ; N-[4-(4-페닐피페라지닐)부틸]-2-나프타미드 ; N-[4-(4-2-메톡시페닐)피페라지닐)부틸]-1-메톡시-2-나프타미드옥살레이트로 이루어진 군으로부터 선택되는 화합물인 것을 특징으로 하는 유도체.
- 약제학적으로 허용가능한 부형제와, 제1항 내지 제3항 중 어느 한 항에 따른 염기 형태 또는 약제학적으로 허용가능한 염의 형태를 갖는 적어도 하나의 유도체를 치료상의 유효량으로 함유하는 것을 특징으로 하는 약제학적 조성물.
- 도파민 D3수용체의 국부작용물질로 작용하는 약제의 제조용으로써 제1항 내지 제3항 중 어느 한 항에 따른 유도체의 용도.
- 제5항에 있어서 도파민 D3수용체를 수반하는 신경정신성 질환, 특히 정신병과 우울증의 치료용, 약물의존증, 특히 금단과 관련된 질환 및/또는 코카인, 헤로인, 알코올, 니코틴 등에 의존한 환자의 해독과 관련된 질환의 치료용 또는 성적인 장애, 특히 성불능증의 치료용 약제 제조용인 것을 특징으로 하는 유도체의 용도.
- 제5항에 있어서, 파킨스병의 상보적 치료용 약제의 제조용인 것을 특징으로 하는 유도체의 용도.
- 제1항 내지 제3항 중 어느 한 항에 따른 적어도 하나의 유도체를 활성 요소로서 함유하는 것을 특징으로 하는 도파민 D3수용체의 국부작용물질로써 작용하는 약제.
- 제8항에 있어서, 도파민 D3수용체를 수반하는 신경정신성 질환, 특히 정신병과 우울증의 치료용, 약물의존증, 특히 금단과 관련된 질환 및/또는 코카인, 헤로인, 알코올, 니코틴 등에 의존한 환자의 해독과 관련된 질환의 치료용 또는 성적인 장애, 특히 성불능증의 치료용인 것을 특징으로 하는 약제
- 제8항에 있어서, 파킨슨병의 상보적 치료용인 것을 특징으로 하는 약제
- 파킨슨병의 상보적 치료용 약제의 제조용으로써 도파민 D3수용체의 작용물질로서 작용하는 것을 특징으로 하는 화합물의 용도.
- 파킨슨병의 상보적 치료용으로써 도파민 D3수용체의 작용물질로서 작용하는 화합물을 활성요소로서 함유하는 것을 특징으로 하는 약제.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9514654 | 1995-12-11 | ||
| FR9514654A FR2742149B1 (fr) | 1995-12-11 | 1995-12-11 | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970042506A true KR970042506A (ko) | 1997-07-24 |
| KR100447033B1 KR100447033B1 (ko) | 2004-11-03 |
Family
ID=9485370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960063733A KR100447033B1 (ko) | 1995-12-11 | 1996-12-10 | 신규한2-나프타미드유도체와이의치료제로서의사용 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5872119A (ko) |
| EP (1) | EP0779284B1 (ko) |
| JP (1) | JPH09291033A (ko) |
| KR (1) | KR100447033B1 (ko) |
| AT (1) | ATE220399T1 (ko) |
| CA (1) | CA2192535C (ko) |
| DE (1) | DE69622246T2 (ko) |
| DK (1) | DK0779284T3 (ko) |
| ES (1) | ES2179919T3 (ko) |
| FR (1) | FR2742149B1 (ko) |
| PT (1) | PT779284E (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020090152A (ko) * | 2001-05-23 | 2002-11-30 | 화이자 프로덕츠 인크. | 우울증 또는 불안증을 위한 배합 치료 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
| WO1998037893A1 (fr) * | 1997-02-26 | 1998-09-03 | Sumitomo Pharmaceuticals Co., Ltd. | Antagoniste du recepteur dopaminergique d4 |
| US6362009B1 (en) | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| JP2003513053A (ja) * | 1999-11-04 | 2003-04-08 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 塩依存性高血圧症の治療におけるドーパミンｄ３受容体アゴニストの使用 |
| AU2001250404A1 (en) * | 2000-03-27 | 2001-10-08 | Basf Aktiengesellschaft | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| US20020103198A1 (en) * | 2000-12-04 | 2002-08-01 | Fliri Anton F.J | Acylamino cyclopropane derivatives |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| CA2486564A1 (en) * | 2002-05-23 | 2003-12-04 | Abbott Laboratories | Acetamides and benzamides that are useful in treating sexual dysfunction |
| DE10232020A1 (de) | 2002-07-04 | 2004-02-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Neurorezeptoraktive Heteroarencarboxamide |
| JP4717006B2 (ja) * | 2003-11-20 | 2011-07-06 | イーライ リリー アンド カンパニー | ビタミンｄ受容体モジュレータ |
| EP1683790A1 (en) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
| CN1948298B (zh) * | 2006-11-09 | 2010-09-01 | 东南大学 | 一种多巴胺d3受体部分激动剂及其应用 |
| US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
| EP2354136B1 (en) | 2008-10-10 | 2016-02-24 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Novel dopamine d3 receptor ligands and preparation and medical uses of the same |
| CN105461608B (zh) * | 2015-11-23 | 2017-11-28 | 东南大学 | 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途 |
| CN105294685B (zh) * | 2015-11-23 | 2017-03-08 | 东南大学 | 六氢吡嗪并喹啉类d3受体配体及其制备方法和用途 |
| JP7017797B2 (ja) * | 2017-02-24 | 2022-02-09 | 深▲チェン▼市霊蘭生物医薬科技有限公司 | 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975439A (en) * | 1987-09-25 | 1990-12-04 | Janssen Pharmaceutical N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| US5254552A (en) * | 1988-05-24 | 1993-10-19 | American Home Products Corporation | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
| US5106849A (en) * | 1988-05-24 | 1992-04-21 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
| US5010078A (en) * | 1988-05-24 | 1991-04-23 | American Home Products Corporation | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity |
| FR2682953B1 (fr) * | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| SE9201138D0 (sv) * | 1992-04-09 | 1992-04-09 | Astra Ab | Novel phthalimidoalkylpiperazines |
| AU4312593A (en) * | 1992-05-18 | 1993-12-13 | Smithkline Beecham Plc | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease |
| US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
| DE69534213T2 (de) * | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
-
1995
- 1995-12-11 FR FR9514654A patent/FR2742149B1/fr not_active Expired - Fee Related
-
1996
- 1996-12-09 ES ES96402672T patent/ES2179919T3/es not_active Expired - Lifetime
- 1996-12-09 PT PT96402672T patent/PT779284E/pt unknown
- 1996-12-09 DK DK96402672T patent/DK0779284T3/da active
- 1996-12-09 AT AT96402672T patent/ATE220399T1/de not_active IP Right Cessation
- 1996-12-09 DE DE69622246T patent/DE69622246T2/de not_active Expired - Fee Related
- 1996-12-09 EP EP96402672A patent/EP0779284B1/fr not_active Expired - Lifetime
- 1996-12-10 KR KR1019960063733A patent/KR100447033B1/ko not_active IP Right Cessation
- 1996-12-10 US US08/762,782 patent/US5872119A/en not_active Expired - Fee Related
- 1996-12-10 CA CA002192535A patent/CA2192535C/fr not_active Expired - Fee Related
- 1996-12-11 JP JP8352076A patent/JPH09291033A/ja active Pending
-
1998
- 1998-06-26 US US09/105,575 patent/US5985895A/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020090152A (ko) * | 2001-05-23 | 2002-11-30 | 화이자 프로덕츠 인크. | 우울증 또는 불안증을 위한 배합 치료 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2192535C (fr) | 2006-05-16 |
| DK0779284T3 (da) | 2002-10-07 |
| EP0779284A1 (fr) | 1997-06-18 |
| US5985895A (en) | 1999-11-16 |
| FR2742149A1 (fr) | 1997-06-13 |
| JPH09291033A (ja) | 1997-11-11 |
| DE69622246D1 (de) | 2002-08-14 |
| US5872119A (en) | 1999-02-16 |
| ATE220399T1 (de) | 2002-07-15 |
| ES2179919T3 (es) | 2003-02-01 |
| CA2192535A1 (fr) | 1997-06-12 |
| EP0779284B1 (fr) | 2002-07-10 |
| DE69622246T2 (de) | 2002-11-07 |
| PT779284E (pt) | 2002-11-29 |
| KR100447033B1 (ko) | 2004-11-03 |
| FR2742149B1 (fr) | 1998-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970042506A (ko) | 신규한 2-나프타미드 유도체와 이의 치료제로서의 사용 | |
| AU738743B2 (en) | Antipruritic | |
| AU2006228413B2 (en) | Treatment of Parkinson's Disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| SE0102036D0 (sv) | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof | |
| ZA200408975B (en) | Novel compounds are their use. | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| KR880012227A (ko) | 도파민 수용체 길항제의 신규사용법 | |
| KR20210074315A (ko) | P2x3 길항제를 사용한 소양증의 치료 | |
| JP2010514733A (ja) | 高眼圧症の治療のためのイソソルビドモノニトレート誘導体 | |
| JP2009538827A (ja) | カンナビノイドおよび使用方法 | |
| EP0413329B1 (en) | 5-Methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases | |
| YU6196A (sh) | Transdermalna flasterska formulacija | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| US4208417A (en) | Indole derivatives and their use as anxiolytics | |
| CA2196809A1 (en) | N-substituted 3-azabicyclo (3.2.0)heptane derivatives useful as neuroleptics | |
| JPH02292218A (ja) | 脳血管性疾患治療剤および抗炎症剤 | |
| EP1623741A2 (en) | Cannabinoid receptor ligands for hair growth modulation | |
| JPWO2002078744A1 (ja) | 精神神経疾患治療薬 | |
| RU2007125636A (ru) | Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина | |
| NZ193379A (en) | Analgesic and/or myotonolytic compositions based on an analgesically active quinazolinone and a centrally active myotonolytic | |
| AU629688B2 (en) | Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists | |
| JPH0352816A (ja) | 腎炎の治療剤 | |
| JPH0525167A (ja) | 緑内障の治療に有用な置換ベンゼン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080722 Year of fee payment: 5 |
|
| LAPS | Lapse due to unpaid annual fee |